[go: up one dir, main page]

HK1258050A1 - 用於治療劑緩釋的胃駐留系統及其使用方法 - Google Patents

用於治療劑緩釋的胃駐留系統及其使用方法

Info

Publication number
HK1258050A1
HK1258050A1 HK19100427.2A HK19100427A HK1258050A1 HK 1258050 A1 HK1258050 A1 HK 1258050A1 HK 19100427 A HK19100427 A HK 19100427A HK 1258050 A1 HK1258050 A1 HK 1258050A1
Authority
HK
Hong Kong
Prior art keywords
therapeutic agent
slow release
retention system
stomach retention
stomach
Prior art date
Application number
HK19100427.2A
Other languages
English (en)
Inventor
Rosemary Kanasty
Andrew Bellinger
Colin Gardner
Tyler Grant
Saumya Singh
Original Assignee
Lyndra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyndra Inc filed Critical Lyndra Inc
Publication of HK1258050A1 publication Critical patent/HK1258050A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK19100427.2A 2015-10-23 2019-01-11 用於治療劑緩釋的胃駐留系統及其使用方法 HK1258050A1 (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562245789P 2015-10-23 2015-10-23
US201562245797P 2015-10-23 2015-10-23
US201562264795P 2015-12-08 2015-12-08
US201562264799P 2015-12-08 2015-12-08
US201562264806P 2015-12-08 2015-12-08
US201662402947P 2016-09-30 2016-09-30
PCT/US2016/058309 WO2017070612A1 (en) 2015-10-23 2016-10-21 Gastric residence systems for sustained release of therapeutic agents and methods of use thereof

Publications (1)

Publication Number Publication Date
HK1258050A1 true HK1258050A1 (zh) 2019-11-01

Family

ID=58558169

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19100427.2A HK1258050A1 (zh) 2015-10-23 2019-01-11 用於治療劑緩釋的胃駐留系統及其使用方法

Country Status (8)

Country Link
US (1) US11576859B2 (zh)
EP (1) EP3364946A4 (zh)
JP (2) JP7085473B2 (zh)
CN (2) CN108472249A (zh)
AU (1) AU2016342374B2 (zh)
CA (1) CA3002916C (zh)
HK (1) HK1258050A1 (zh)
WO (1) WO2017070612A1 (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
WO2015191922A1 (en) 2014-06-11 2015-12-17 Massachusetts Institute Of Technology Enteric elastomers
CN108472249A (zh) 2015-10-23 2018-08-31 林德拉有限公司 用于治疗剂缓释的胃驻留系统及其使用方法
EP3386488B1 (en) 2015-12-08 2023-09-06 Lyndra Therapeutics, Inc. Geometric configurations for gastric residence systems
AU2017268840B2 (en) * 2016-05-27 2022-02-10 Lyndra Therapeutics, Inc. Materials architecture for gastric residence systems
US11576866B2 (en) 2016-09-30 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
US11541015B2 (en) 2017-05-17 2023-01-03 Massachusetts Institute Of Technology Self-righting systems, methods, and related components
BR112019023985A2 (pt) 2017-05-17 2020-06-09 Massachusetts Inst Technology sistema de autocorreção e componentes e métodos relacionados
WO2018227147A1 (en) * 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
KR102046395B1 (ko) * 2017-12-12 2019-11-19 동아에스티 주식회사 베포타스틴 또는 이의 약제학적으로 허용 가능한 염을 포함하는 서방성 제제
JP2021530253A (ja) * 2018-03-29 2021-11-11 マティ セラピューティクス，インク． 眼科用徐放性製剤およびドライアイ症候群治療のための使用
WO2019222570A1 (en) 2018-05-17 2019-11-21 Massachusetts Institute Of Technology Systems for electrical stimulation
WO2019245925A1 (en) 2018-06-19 2019-12-26 National University Of Singapore Formulations of 5-hydroxy tryptophan (5-htp) for better bioavailability for various indications
WO2020117855A1 (en) * 2018-12-03 2020-06-11 Lyndra, Inc. Stomach simulating device
US11771829B2 (en) 2019-02-01 2023-10-03 Massachusetts Institute Of Technology Systems and methods for liquid injection
JP2022553862A (ja) * 2019-11-08 2022-12-26 リンドラ セラピューティクス， インコーポレイティド 活性剤投与用胃内滞留型システム
JP2022554375A (ja) * 2019-11-08 2022-12-28 リンドラ セラピューティクス， インコーポレイティド 胃内滞留システム用の高分子リンカー
US11541216B2 (en) 2019-11-21 2023-01-03 Massachusetts Institute Of Technology Methods for manufacturing tissue interfacing components
CN116234540A (zh) 2020-07-29 2023-06-06 赛康特集团有限责任公司 具有包括交联聚(癸二酸甘油酯)的结构的形状引导控释和滞留
CA3217611A1 (en) * 2021-05-05 2022-11-10 Nupura BHISE Gastric residence systems comprising buprenorphine and naloxone
CA3216743A1 (en) * 2021-05-05 2022-11-10 Estelle BEGUIN Gastric residence systems comprising methadone
KR20240039030A (ko) 2021-07-30 2024-03-26 에벡시아 테라퓨틱스 아이엔씨. 5-하이드록시트립토판 위체류성 투여 형태
JP2024535585A (ja) 2021-10-14 2024-09-30 エヴェクシア セラピューティクス， インク． 脳内５－ヒドロキシトリプタミンの機能を治療目的で最適化する方法
JP2025502426A (ja) * 2022-01-19 2025-01-24 リンドラ セラピューティクス， インコーポレイティド 胃内滞留のための剤形

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1957564A (en) 1932-11-23 1934-05-08 Aubra T West Expanding capsule body
US3154461A (en) 1960-03-07 1964-10-27 Minnesota Mining & Mfg Matte-finish polymeric film and method of forming the same
US3531368A (en) 1966-01-07 1970-09-29 Toray Industries Synthetic filaments and the like
US3716614A (en) 1969-05-12 1973-02-13 Toray Industries Process of manufacturing collagen fiber-like synthetic superfine filament bundles
AU449029B2 (en) 1969-08-28 1974-04-17 Commonwealth Scientific And Industrial Research Organisation Device for administration to ruminants
JPS5512411B2 (zh) 1974-03-12 1980-04-02
US4304767A (en) 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
FI75816C (fi) 1981-02-06 1988-08-08 Ucb Sa Foerfarande foer framstaellning av terapeutiskt aktiv 2-/4-(difenylmetyl)-1-piperazinyl/-aettiksyror eller dess amid.
US4451260A (en) 1982-03-26 1984-05-29 Minnesota Mining And Manufacturing Company Sustained release oral medicinal delivery device
US4676507A (en) 1985-05-06 1987-06-30 Patterson Bruce D Puzzles forming platonic solids
US4735804A (en) * 1985-05-10 1988-04-05 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
DE3680024D1 (de) 1985-05-10 1991-08-08 Merck & Co Inc Abgabesystem fuer arzneimittel, das waehrend einer kontrollierten zeitspanne im magen zurueckgehalten werden kann.
JPS6226215A (ja) * 1985-05-10 1987-02-04 メルク　エンド　カムパニ−　インコ−ポレ−テツド 一定に制御した時間内胃中に保持できる薬剤移送装置
US4767627A (en) * 1985-05-29 1988-08-30 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
US4758436A (en) 1985-05-29 1988-07-19 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
EP0253554A3 (en) 1986-07-15 1988-07-20 Pfizer Inc. Controlled release drug-containing fibers
CA1314742C (en) 1986-12-12 1993-03-23 Hiromu Terada Optical fiber array
IL87710A (en) 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
US5002772A (en) 1988-05-31 1991-03-26 Pfizer Inc. Gastric retention system for controlled drug release
NZ228382A (en) * 1989-03-17 1992-08-26 Carter Holt Harvey Plastic Pro Drug administering coil-like device for insertion in body cavity of animal
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
JPH03163011A (ja) 1989-08-31 1991-07-15 Yamanouchi Pharmaceut Co Ltd 胃内滞留デバイス
US5047464A (en) 1989-09-20 1991-09-10 Merck & Co., Inc. Bioerodible thermoset elastomers
US5121329A (en) 1989-10-30 1992-06-09 Stratasys, Inc. Apparatus and method for creating three-dimensional objects
JP3128934B2 (ja) 1991-03-28 2001-01-29 富士電機株式会社 モールド変圧器とそのモールド方法
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5939467A (en) 1992-06-26 1999-08-17 The Procter & Gamble Company Biodegradable polymeric compositions and products thereof
US5369142A (en) 1993-01-15 1994-11-29 The Ohio State University Water soluble polymers containing amino acid residues for dental restoratives
JP2750802B2 (ja) 1993-01-29 1998-05-13 日進工業 株式会社 物体表面の洗滌・剥離方法とその装置
JP2983800B2 (ja) 1993-05-17 1999-11-29 三洋電機株式会社 部品位置認識装置
WO1995003558A1 (en) 1993-07-19 1995-02-02 Reflexite Corporation Retroreflective structure
DE4406424A1 (de) * 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
US5837276A (en) 1994-09-02 1998-11-17 Delab Apparatus for the delivery of elongate solid drug compositions
EP0820258B1 (en) 1995-03-23 2002-10-09 Advanced Animal Technology Limited Substance delivery device
US6962579B2 (en) 1995-03-23 2005-11-08 Advanced Animal Technology Limited Substance delivery device
US5614324A (en) 1995-07-24 1997-03-25 Gould Electronics Inc. Multi-layer structures containing a silane adhesion promoting layer
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
AU2521797A (en) 1996-04-12 1997-11-07 Japan Atomic Energy Research Institute Ph-sensitive polymers
PT1003476E (pt) * 1997-08-11 2005-05-31 Alza Corp Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica
DE19850309A1 (de) 1998-10-30 2000-05-04 Lohmann Therapie Syst Lts Expandierbares gastroretensives Therapiesystem mit verlängerter Magenverweildauer
IL133196A0 (en) 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
EP1286663B1 (en) 2000-05-18 2006-01-18 Therics, Inc. Encapsulating a toxic core within a non-toxic region in an oral dosage form
US20020022048A1 (en) 2000-05-26 2002-02-21 Bromberg Lev E. Composite wafer for controlled drug delivery
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US8158143B2 (en) 2000-07-14 2012-04-17 Helmholtz-Zentrum Geesthacht Zentrum Fuer Material- Und Kuestenforschung Gmbh Systems for releasing active ingredients, based on biodegradable or biocompatible polymers with a shape memory effect
US7803392B2 (en) 2000-12-27 2010-09-28 University Of Kentucky Research Foundation pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules
US6627206B2 (en) 2001-07-25 2003-09-30 Greg A. Lloyd Method and apparatus for treating obesity and for delivering time-released medicaments
WO2003015745A1 (en) 2001-08-16 2003-02-27 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Expandable gastric retention device
US20040219186A1 (en) 2001-08-16 2004-11-04 Ayres James W. Expandable gastric retention device
WO2003061606A1 (en) 2002-01-23 2003-07-31 Uab Research Foundation Glass-ionomer cements containing amino acids
AU2003234159A1 (en) 2002-04-22 2003-11-03 Purdue Research Foundation Hydrogels having enhanced elasticity and mechanical strength properties
DE10224352A1 (de) 2002-06-01 2003-12-11 Mueller Schulte Detlef Thermosensitive Polymerträger mit veränderbarer physikalischer Struktur für die biochemische Analytik, Diagnostik und Therapie
GB0214013D0 (en) 2002-06-18 2002-07-31 Euro Celtique Sa Pharmaceutical product
MY142179A (en) 2002-07-25 2010-10-15 Glaxo Group Ltd Multicomponent pharmaceutical dosage form
AU2003282603A1 (en) 2002-10-11 2004-05-04 Depomed Development Ltd Gastro-retentive levodopa delivery form
BRPI0407682A (pt) 2003-02-19 2006-03-01 Mnemoscience Gmbh dispositivo auto-expandìvel para a área gastrointestinal ou urugenital
JP4497833B2 (ja) 2003-04-21 2010-07-07 富士フイルム株式会社 ポジ型平版印刷版原版
US7662864B2 (en) * 2003-06-04 2010-02-16 Rutgers, The State University Of New Jersey Solution polymerization processes to prepare a polymer that degrades to release a physiologically active agent
EP1633281A1 (de) 2003-06-13 2006-03-15 Mnemoscience GmbH Stents
EP1638533A1 (en) 2003-06-18 2006-03-29 John Michael Newton Controlled release devices with lumens
US20090259236A2 (en) 2003-07-28 2009-10-15 Baronova, Inc. Gastric retaining devices and methods
US8048169B2 (en) 2003-07-28 2011-11-01 Baronova, Inc. Pyloric valve obstructing devices and methods
US6825308B1 (en) 2003-10-29 2004-11-30 Council Of Scientific And Industrial Research Copolymers and preparation thereof
DE10350556A1 (de) 2003-10-29 2005-06-02 Clariant Gmbh Wasserbasierende Pigmentpräparationen
WO2005056708A2 (en) 2003-12-09 2005-06-23 Spherics, Inc. Bioadhesive polymers with catechol functionality
US20050163858A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Ziprasidone formulations
US20080089933A1 (en) 2006-10-16 2008-04-17 Amir Alon Device and method for reducing calorie intake
TW200539903A (en) * 2004-03-12 2005-12-16 Smithkline Beecham Plc Pharmaceutical formulations
US7964196B2 (en) 2004-05-25 2011-06-21 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
DE102004047076A1 (de) 2004-09-28 2006-04-06 Zimmer Ag Verfahren zur Herstellung von Polyestern
IL166183A0 (en) 2005-01-06 2006-01-15 Yissum Res Dev Co Novel diagnostic and imaging techniques of the gi tract
CA2596529C (en) 2005-01-27 2014-08-19 Corium International, Inc. Hydrophilic biocompatible adhesive formulations and uses
US20080153779A1 (en) 2005-02-01 2008-06-26 Jun Liao Gastric Retention and Controlled Release Delivery System
US7785291B2 (en) 2005-03-01 2010-08-31 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
JP2006323082A (ja) 2005-05-18 2006-11-30 Canon Inc 現像剤補給容器
US8021384B2 (en) 2005-07-26 2011-09-20 Ram Weiss Extending intrabody capsule
CN101175571A (zh) 2005-08-05 2008-05-07 滋贺县 含有共混聚合物而成的液体中物质转移材料
US20070048383A1 (en) 2005-08-25 2007-03-01 Helmus Michael N Self-assembled endovascular structures
EP1957052A2 (en) 2005-10-25 2008-08-20 Pharmascience Inc. A gastric retention drug delivery system
EP1945189A4 (en) 2005-11-03 2012-08-15 Sun Pharmaceutical Ind Ltd COATED TABLETS WITH EXTENDED MAGNETIC RETENTION
US7674396B2 (en) 2005-11-08 2010-03-09 Plensat Llc Method and system for treatment of eating disorders
EP1981465B1 (en) 2006-01-18 2015-11-04 Intec Pharma Ltd. Method for forming delivery devices for oral intake of an agent
CA2642479C (en) 2006-02-15 2014-08-19 Intec Pharma Ltd. A gastro-retentive system for the delivery of macromolecules
CA2644694C (en) 2006-03-10 2014-05-13 Sangeeta N. Bhatia Triggered self-assembly conjugates and nanosystems
US7691151B2 (en) 2006-03-31 2010-04-06 Spiration, Inc. Articulable Anchor
US20070264307A1 (en) 2006-05-15 2007-11-15 Medtronic Vascular, Inc. Biodegradable Modified Caprolactone Polymers for Fabricating and Coating Medical Devices
EP1886665A1 (en) 2006-08-01 2008-02-13 Boehringer Ingelheim Pharma GmbH & Co. KG Gastro retentive delivery system
JP2010502591A (ja) 2006-09-04 2010-01-28 パナセア バイオテック リミテッド プログラム可能な浮揚性送達技術
US20080075766A1 (en) 2006-09-25 2008-03-27 Shun-Por Li Multi-core dosage form having transparent outer coating
WO2008079404A2 (en) 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
US8507778B2 (en) 2007-03-13 2013-08-13 Arthur J. Olson Self-assembled polyhedra
WO2008111077A2 (en) 2007-03-13 2008-09-18 Technion Research & Development Foundation Ltd. Self-assembled polyhedral multimeric chemical structures
WO2008124122A1 (en) 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent and glitazones
MX337286B (es) 2007-05-25 2016-02-22 Indivior Uk Ltd Formulaciones de transferencia sostenida de compuestos de risperidona.
US8481076B2 (en) 2007-05-25 2013-07-09 Gorham Enterprises Llc Bariatric magnetic apparatus and method of manufacturing thereof
US8038659B2 (en) 2007-10-17 2011-10-18 The Invention Science Fund I, Llc Disintegrating digestive tract interaction system
US8637455B2 (en) 2007-10-22 2014-01-28 Affinergy, Llc Compositions and methods for delivery of glycopeptide antibiotics to medical device surfaces
US20110097395A1 (en) 2008-03-08 2011-04-28 Najib Babul Oral Pharmaceutical Compositions of Buprenorphine and Method of Use
EP2262484B1 (en) 2008-03-11 2013-01-23 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US20130273135A1 (en) 2008-03-25 2013-10-17 University Of Utah Research Foundation Controlled Release Combination Biomaterials
SI2276473T1 (sl) 2008-04-18 2017-02-28 Intec Pharma Ltd. Gastro retencijsko dajanje zdravila karbidope/levodope
EP2280670A4 (en) 2008-04-28 2012-08-01 Eatlittle Inc BÉZOARD TRAINING UNITS FOR WEIGHT CONTROL
US20100256342A1 (en) 2008-08-12 2010-10-07 Francis Raymond Salemme Protein nodes for controlled nanoscale assembly
EP2329810A4 (en) 2008-08-18 2012-09-19 Team Academy Of Pharmaceutical Science DRUG DISPENSING SYSTEM WITH MAGNETIC RETENTION, MANUFACTURING PROCESS AND APPLICATION
WO2010035273A2 (en) 2008-09-29 2010-04-01 Intec Pharma Ltd. Novel gastroretentive delivery system
CN102245127B (zh) 2008-10-10 2014-06-11 雷瓦医药公司 可扩展的滑动和锁定支架
JP2012510987A (ja) 2008-12-04 2012-05-17 インテック ファーマ リミテッド ザレプロン胃内滞留性薬剤送達システム
EP2373232A2 (en) * 2008-12-27 2011-10-12 Chandra S. Duggirala Devices for treating obesity and methods of using those devices
CN102414116B (zh) 2009-02-26 2015-01-21 加利福尼亚大学董事会 用于制备尺寸可控的纳米颗粒的超分子方法
US8414559B2 (en) 2009-05-07 2013-04-09 Rainbow Medical Ltd. Gastroretentive duodenal pill
DE102009028076A1 (de) 2009-07-29 2011-02-03 Evonik Röhm Gmbh Beschichtungsmittel zum Tauchbeschichten von Kapselhälften
US20110052700A1 (en) 2009-08-31 2011-03-03 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of levosulpiride
WO2011032087A2 (en) 2009-09-11 2011-03-17 Replication Medical Inc. Swellable polymeric device for dietary regulation
EP2490677A2 (en) 2009-10-19 2012-08-29 Intec Pharma Ltd. Novel gastroretentive dosage forms of poorly soluble drugs
US9421169B2 (en) 2009-11-20 2016-08-23 Covidien Lp Oral dosage forms for delivery of therapeutic agents
CN101711752B (zh) 2009-11-26 2011-09-21 中国科学院上海药物研究所 一种苯并异噁唑类衍生物的控释制剂及其制备方法
US11535510B2 (en) 2010-04-27 2022-12-27 The Johns Hopkins University Self-folding sub-centimeter structures
AU2011276170B2 (en) 2010-07-06 2016-03-10 Grunenthal Gmbh Novel gastro- retentive dosage forms comprising a GABA Analog and an opioid
PL3517101T3 (pl) 2010-08-05 2021-02-22 Taris Biomedical Llc Wszczepiane urządzenia do podawania leków w miejscach moczowo-płciowych
US20120165792A1 (en) 2010-12-22 2012-06-28 Ethicon Endo-Surgery, Inc. Pill Catchers
US20120165794A1 (en) 2010-12-22 2012-06-28 Ethicon Endo-Surgery, Inc. Pill Catchers
US20120165793A1 (en) 2010-12-22 2012-06-28 Ethicon Endo-Surgery, Inc. Pill Catchers
EP2670398B1 (en) 2011-02-04 2017-06-07 TARIS Biomedical LLC Implantable device for controlled release of low solubility drug
US9228859B2 (en) 2011-09-26 2016-01-05 Northeastern University Customizable embedded sensors
ES2603278T3 (es) 2011-12-09 2017-02-24 Purdue Pharma Lp Formas farmacéuticas de dosificación que comprenden poli (epsilon-caprolactona) y óxido de polietileno
US8979885B2 (en) 2012-02-24 2015-03-17 Elwha Llc Devices, systems, and methods to control stomach volume
AU2013290875A1 (en) 2012-07-16 2015-02-05 APET Holding B.V. Gastro-retentive drug delivery system
US9307966B2 (en) 2012-08-15 2016-04-12 St. Jude Medical Puerto Rico Llc Vascular closure device anchor
MX2015001917A (es) 2012-08-16 2015-10-29 Teva Pharma Composiciones farmaceuticas de memantina.
US10441760B2 (en) 2013-03-01 2019-10-15 The Johns Hopkins University Self-actuating chemomechanical devices for delivery and extended release of therapeutic agents in the gastrointestinal tract
CN103654903A (zh) 2013-11-27 2014-03-26 西安交通大学 一种用于人体消化道吻合的磁性可降解装置
ES2926480T3 (es) 2013-12-05 2022-10-26 Epitomee Medical Ltd Dispositivos y sistemas retentivos para la liberación in situ de principios activos farmacéuticos
WO2015168297A1 (en) 2014-04-29 2015-11-05 Massachusetts Institute Of Technology Polymeric materials for bio-applications
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
CN106535878B (zh) 2014-06-02 2022-11-01 科莱西奥生物科技有限公司 可张开的胃内滞留剂型
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
WO2015191922A1 (en) 2014-06-11 2015-12-17 Massachusetts Institute Of Technology Enteric elastomers
JP2018515476A (ja) 2015-05-01 2018-06-14 マサチューセッツ インスティテュート オブ テクノロジー 誘発性形状記憶誘導デバイス
CN108472249A (zh) 2015-10-23 2018-08-31 林德拉有限公司 用于治疗剂缓释的胃驻留系统及其使用方法
EP3383365A1 (en) 2015-12-01 2018-10-10 Clexio Biosciences Ltd. Gastric retentive devices
AU2016362794B2 (en) 2015-12-02 2019-05-09 Clexio Biosciences Ltd. Device for preparing gastroretentive dosage forms
EP3386488B1 (en) 2015-12-08 2023-09-06 Lyndra Therapeutics, Inc. Geometric configurations for gastric residence systems
AU2017268840B2 (en) 2016-05-27 2022-02-10 Lyndra Therapeutics, Inc. Materials architecture for gastric residence systems
US11576866B2 (en) 2016-09-30 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
US20200230244A1 (en) 2016-11-09 2020-07-23 Massachusetts Institute Of Technology Triggerable hydrogel compositions and related methods
CN110035718B (zh) 2016-12-02 2021-04-06 克雷西奥生物科技有限公司 胃内滞留系统
JP6226215B1 (ja) 2017-04-21 2017-11-08 株式会社Ｒｅｓｅａｒｃｈ Ｍｉｎｄ せん妄を治療又は予防するための併用療法
WO2018227147A1 (en) 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
AU2018337837B2 (en) 2017-09-20 2024-03-07 Lyndra Therapeutics, Inc. Encapsulation of gastric residence systems
US11547839B2 (en) 2017-12-04 2023-01-10 Clexio Biosciences Ltd. Long acting gastric residence system
US11576860B2 (en) 2018-05-31 2023-02-14 Massachusetts Institute Of Technology Retrieval systems and related methods
US20220008701A1 (en) 2018-11-15 2022-01-13 Massachusetts Institute Of Technology Millineedle systems for esophageal drug delivery

Also Published As

Publication number Publication date
CN108472249A (zh) 2018-08-31
JP2022116316A (ja) 2022-08-09
AU2016342374A1 (en) 2018-06-07
CA3002916A1 (en) 2017-04-27
JP7085473B2 (ja) 2022-06-16
JP2019501110A (ja) 2019-01-17
CA3002916C (en) 2024-06-11
US20180311154A1 (en) 2018-11-01
JP7448587B2 (ja) 2024-03-12
EP3364946A4 (en) 2019-06-26
AU2016342374B2 (en) 2022-08-04
US11576859B2 (en) 2023-02-14
WO2017070612A1 (en) 2017-04-27
EP3364946A1 (en) 2018-08-29
CN118975972A (zh) 2024-11-19

Similar Documents

Publication Publication Date Title
HK1258050A1 (zh) 用於治療劑緩釋的胃駐留系統及其使用方法
BR112016018570A2 (pt) método e aparelho para administração supracoroidal de agente terapêutico
HK1250376A1 (zh) 用於癌症的治療和診斷方法
IL248730B (en) Drug delivery system and method of use
BR112017017882A2 (pt) sistema para e método de tratamento de aneurismas
IL245094A0 (en) A medical device for repairing the left auricle and related systems and methods
DK3295951T3 (da) Anti-pvrig-antistoffer og fremgangsmåder for anvendelse
BR112017002511A2 (pt) sistemas e métodos de almofada terapêutica
DK3024497T3 (da) Fremgangsmåder og præparater til behandling af hjernesygdomme
IL259801A (en) ezh2 inhibitors and methods of using them
HK1248229A1 (zh) Pi3k抑制劑的鹽及其製備方法
LT3277842T (lt) Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais
EP3681479A4 (en) METHOD OF ADMINISTRATION AND TREATMENT
IL261343A (en) Transposon system and methods of use
IL253796A0 (en) Therapeutically active compounds and methods of use
DK3264886T3 (da) System og fremgangsmåde til observation af pattegrisefødsel
HK1254191A1 (zh) 多矢量患者電極系統和使用的方法
SG11201703202YA (en) Method and system for detection of disease agents in blood
HK1222331A1 (zh) 修飾的繆勒抑制物質 蛋白及其用於疾病治療的用途
GB2533024B (en) Device and system for treatment of fish
IL265955A (en) Therapeutic compounds and methods of use thereof
IL261476B (en) A system and method for in-line treatment of thread for use with a thread consumption device
PL3285636T3 (pl) Układ foroptera i sposób jego użycia
RS65120B1 (sr) Farmaceutske formulacije i postupci za njihovu upotrebu
IL256127B (en) Use of benzimidazole history for nocturnal acid reflux

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE NAME OF THE INVENTOR: FROM SINGH, SAUMYA TO MOORTHY, SAUMYA